HC Wainwright & Co. reiterates Buy rating on Adagene, $7 price target
HC Wainwright & Co. reiterated a Buy rating on Adagene with a $7 price target, implying a 239.8% upside from the Oct 16 close of $2.06. The firm cited positive clinical developments, including progress in Phase 1 studies for ADG138 and ADG126, and upcoming data readouts for muzastotug in combination with pembrolizumab.
How this was made

The 30-second read
Why it matters
The rating change adds a short‑term bullish bias, but the lack of efficacy data tempers the upside.
Market read
Analyst upgrade with a high price target may attract short‑term buying interest in ADGE.
What to watch
Trial enrollment timelines and regulatory hurdles could delay any upside.
Background
Adagene is a clinical‑stage biotech developing antibody‑drug conjugates. The analyst note highlights early trial activity and a new $7 price target.
Market effects
Positive sentiment may spill to other early‑stage biotech stocks.
Limited to US biotech sector.
Minor, confined to investors tracking clinical‑trial pipelines.
Counterpoint
Without data readouts, the upgrade may be premature; risk of disappointment remains.
Key entities
- analystHC Wainwright & Co.
Equity research firm that issued the Buy rating and price target.
- companyAdagene
Biotech firm developing ADG138 and ADG126 (muzastotug).
